Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
AstraZeneca
Mallinckrodt
Moodys
Medtronic

Last Updated: January 30, 2023

Flutemetamol f-18 - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for flutemetamol f-18 and what is the scope of freedom to operate?

Flutemetamol f-18 is the generic ingredient in one branded drug marketed by Ge Healthcare and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Flutemetamol f-18 has eighty-three patent family members in twenty-four countries.

One supplier is listed for this compound.

Summary for flutemetamol f-18
International Patents:83
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 3
Clinical Trials: 19
Patent Applications: 353
What excipients (inactive ingredients) are in flutemetamol f-18?flutemetamol f-18 excipients list
DailyMed Link:flutemetamol f-18 at DailyMed
Recent Clinical Trials for flutemetamol f-18

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Yale UniversityPhase 1
Shanghai Mental Health CenterPhase 4
Maastricht University Medical CenterPhase 2/Phase 3

See all flutemetamol f-18 clinical trials

Pharmacology for flutemetamol f-18

US Patents and Regulatory Information for flutemetamol f-18

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for flutemetamol f-18

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 See Plans and Pricing See Plans and Pricing
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 See Plans and Pricing See Plans and Pricing
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for flutemetamol f-18

Country Patent Number Title Estimated Expiration
Russian Federation 2475267 РАДИОФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (RADIOPHARMACEUTICAL COMPOSITION) See Plans and Pricing
Canada 2438032 DERIVES DE BENZOTHIAZOLE ET COMPOSITIONS ET UTILISATIONS CONNEXES (BENZOTHIAZOLE DERIVATIVE COMPOUNDS, COMPOSITIONS AND USES) See Plans and Pricing
Cyprus 1113334 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for flutemetamol f-18

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2182988 122015000017 Germany See Plans and Pricing PRODUCT NAME: FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
2182988 SPC/GB15/012 United Kingdom See Plans and Pricing PRODUCT NAME: FLUTEMETAMOL (18F) OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF; REGISTERED: UK EU/1/14/941 20140826
1611115 2015/004 Ireland See Plans and Pricing PRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
McKinsey
Moodys
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.